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Abstract
African horse sickness is a devastating, transboundary animal disease, that is ‘listed’ by the Office International des
Epizooties (OIE). Although attenuated, inactivated and subunit vaccines have been developed for African horse sickness
virus (AHSV), these are serotype-specific and their effective deployment therefore relies on rapid and reliable identification
of virus type. AHSV serotype is controlled by the specificity of interactions between neutralising antibodies, and
components of the outer-capsid, particularly protein VP2 (encoded by AHSV genome segment 2 (Seg-2)). We report the
development and evaluation of novel gel based reverse transcription-PCR (RT–PCR) assays targeting AHSV Seg-2, which can
be used to very significantly increase the speed and reliability of detection and identification (compared to virus
neutralisation tests) of the nine serotypes of AHSV. Primer sets were designed targeting regions of Seg-2 that are conserved
between strains within each of the AHSV serotype (types 1 to 9). These assays were evaluated using multiple AHSV strains
from the orbivirus reference collection at IAH (www.reoviridae.org/dsRNA_virus_proteins/ReoID/AHSV-isolates.htm). In each
case the Seg-2 primers showed a high level of specificity and failed to cross-amplify the most closely related heterologous
AHSV types, or other related orbiviruses (such as bluetongue virus (BTV), or equine encephalosis virus (EEV)). The assays are
rapid and sensitive, and can be used to detect and type viral RNA in blood, tissue samples, or cultivated viral suspensions
within 24 h. They were used to identify AHSV strains from recent outbreaks in sub-Saharan African countries. These
methods also generate cDNAs suitable for sequencing and phylogenetic analyses of Seg-2, identifying distinct virus lineages
within each virus-type and helping to identify strain movements/origins. The RT-PCR methods described here provide a
robust and versatile tool for rapid and specific detection and identification of AHSV serotypes 1 to 9.
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Introduction
African horse sickness virus is a distinct virus species within the
genus Orbivirus (of which Bluetongue virus is the ‘type species’), within
the family Reoviridae. African horsesickness (AHS) is an important
transboundary disease that is ‘listed’ by the Office International
des Epizooties (OIE). It is an acute or sub-acute, non-contagious,
arthropod-borne viral disease, characterized by severe pyrexia,
widespread haemorrhages and oedematous exudations [1]. AHS
has case fatality levels as high as 95% in horses and 80% in mules,
while donkeys and zebras show few if any clinical signs and are
thought to act as ‘reservoir’ hosts [2,3]. The African horse sickness
virus (AHSV) can also infect large carnivores via an oral route and
may be a factor in the viability of endangered wildlife populations
[4,5].
AHS is endemic in sub-Saharan Africa [6] but single AHSV
serotypes have occasionally expanded outside these boundaries,
persisting in newly affected areas for a number of years [7]. In
1959–61 an outbreak caused by AHSV serotype 9 (AHSV-9)
occurred in the Middle East, spreading as far as Pakistan and
India, causing heavy mortality in equids [8]. In 1965, AHSV-9
caused an outbreak that started in North Africa but spread as far
as southern Spain [7,9]. In the late 1980s importation of a zebra
infected with AHSV-4 from Namibia, caused an outbreak in Spain
and Portugal [7,10,11,12]. These incursions demonstrate that the
geographic area suitable for successful transmission of AHSV is
much greater than its current endemic zone and suggest that if
AHS become fully established in Europe, it could inflict massive
losses on the equine industry. Control measures have therefore
been put in place by the European Community to regulate
movements of equids [13] and combat this disease [14].
More recently (in 2007) AHSV-4 was identified in horses in
Kenya, AHSV-2 and AHSV-7 in Senegal (ProMed Archivenumber:
20070915.3066, 20070911.3005, 20070825.2788, 20070627.2074,
and 20070623.2031), Nigeria (ProMed Archive number: 20070308.
0815, 20070131.0399), Ghana, Mali and Mauritania [7] and AHSV-
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e256869 was identified in Gambia in 2007, 2009 [15]. In 2008, AHSV-2 was
also reported inEthiopia (ProMed Archive number: 20080930.3087).
There has subsequently been a major further increase in the number
of AHSV types circulating in Ethiopia, with detection of AHSV
serotypes 2, 4, 6, 8 and 9 during 2010 (Bankowska et al – in
preparation).
Bluetongue virus (BTV) and AHSV are transmitted by similar
Culicoides vector species [16]. Changes in the global distribution of
BTV, with massive outbreaks caused by multiple BTV serotypes
throughout Europe (since 1998), incursions into the south-eastern
USA by previously exotic virus types, and detection of BTV-2 and
7 in Australia [17,18] have been linked to a combination of
increased international trade, recruitment of novel vector species,
climate change and its effects on vector distribution [19,20]. There
have also been changes in the distribution of Epizootic
haemorrhagic disease virus (EHDV), AHSV, and equine enceph-
alosis virus (EEV) [21], suggesting that they could also emerge to
pose important threats to European/global livestock and wildlife
populations.
The AHSV genome consists of 10 segments of linear double-
stranded RNA that encode seven structural proteins (VP1 to VP7)
and four distinct non-structural proteins (NS1, NS2, NS3/NS3a
and NS4) [22,23,24,25,26,27]. The surface of the AHSV capsid is
composed of VP2 (encoded by genome segment 2 (Seg-2)) and
VP5 (encoded by Seg-6), which are primarily involved in cell
attachment and penetration during initiation of infection. The
specificity of reactions between these outer-capsid proteins
(particularly VP2) and neutralising antibodies generated by the
mammalian host can be used to identify and distinguish nine
AHSV serotypes in serum neutralisation tests (SNT) or virus
neutralisation tests (VNT) [28,29,30,31,32,33,34].
Based on field observations, these different AHSV serotypes
have previously been linked to differences in immunogenicity,
production of different disease patterns and virulence [35,36].
However, the multi-segmented nature of the AHSV genome and
the potential for field strains to efficiently exchange/reassort
genome segments, suggest that these characteristics may not be
solely due those genome segments or proteins that control serotype
[37]. Recent experiences with the control of BTV-1 and 8 in
northern Europe indicate that vaccination of horses against the
AHSV serotype responsible for an outbreak would provide an
effective control measure. However, rapid deployment of an
appropriate vaccine strain depends on identification of the
serotype involved, as quickly and accurately as possible.
Conventional serotyping methods rely on AHSV isolation from
clinical specimens, in suckling mouse brain and adaptation to
tissue culture (BHK-21, Vero or KC (Culicoides soronensis) cells),
followed by serological assays (VNT), taking a minimum of 3–4
weeks. Alternatively it may be possible to identify the virus
serotype by the reaction of antisera from an infected animal with
reference strains of each AHSV serotype. However, these methods
require access to stocks of well characterised reference antisera or
reference virus strains for each serotype and cannot distinguish
individual virus strains within a single orbivirus serotype.
Consequently they are unsuitable for high precision ‘molecular’
epidemiological studies to differentiate closely related virus
lineages, or topotypes. They can also be complicated by co-
circulation of different viruses, leading to the generation of a
broadly cross-reactive neutralising-antibody responses after se-
quential infection with more than one serotype [38]. The resulting
delays in vaccine deployment could allow the early spread and
consequently the duration of an epizootic.
Serotype-specific RT-PCR assays have been developed for the
26 serotypes of BTV [39,40,41]. Attempts to design similar
primers and typing assays targeting Seg-2 of AHSV [42] have
previously been hampered by a lack of full length Seg-2 sequence
data for all AHSV serotypes. Generation of sequence data for Seg-
2 from multiple reference and field strains of the nine serotypes of
AHSV [31,43, Bankowska et al – manuscript in preparation] has
clarified the level and extent of sequence variation within and
between different serotypes.
We describe the design and in silico evaluation of Seg-2 based
oligonucleotide primers and RT-PCR assays for each AHSV
serotype. Assay specificity was evaluated with a range of AHSV
isolates from dsRNA virus reference collection at IAH [44]. They
were also used to identify AHSV strains circulating in East and
West Africa, using RNA samples extracted directly from diagnostic
blood or tissue samples. These techniques remove the need for
virus isolation and ‘reference antisera’, increasing the speed and
availability of virus identification methods, and reducing the use of
experimental animals.
Materials and Methods
AHSV reference and field isolates
Different AHSV isolates (listed in Table 1) from the Institute for
Animal Health (IAH) ‘Orbivirus Reference Collection’ (ORC)
[44] were grown in BHK-21 clone 13 (European Collection of
Animal cell Cultures (ECACC – 84100501))/Vero (ECACC –
84113001) cell monolayers, until 40–100% cytopathic effect (CPE)
was observed and in C. sonorensis (KC) cells (originally provided by
colleagues at the USDA lab in Laramie, Wyoming) for 7 days. The
field samples used in these studies were taken from naturally
infected animals in the field, by qualified veterinarians, as part of
normal veterinary care and diagnostic testing procedures in the
respective countries. No samples were taken from animals
specifically for these studies, so we believe that ethical approval
is not required.
Extraction of Viral dsRNA
RNA was extracted from BTV infected cell pellets using TrizolH
(Invitrogen) [45], or from cell-free tissue culture supernatant using
the QIAamp Viral RNA Mini Kit (Qiagen), or a Universal
BioRobot (Qiagen), according to manufacturer’s instructions.
Group specific RT-PCR assay
RNA samples extracted from clinical samples or cell culture
material, were tested in duplicate by conventional RT-PCR assays
using AHSV genome segment 7 (Seg-7) specific primers [46].
Samples that generated a strong cDNA band of the expected size
(1179 Kb), were considered to contain AHSV RNA and were used
for further processing/testing.
Serotype specific RT-PCR assays
Multiple primer-pairs were designed based on sequence data for
Seg-2, targeting each of the nine AHSV serotypes (Table S1).
cDNA copies were reverse transcribed from denatured dsRNA
templates, then amplified by One-Step RT-PCR kit (Qiagen) as
described by Mertens et al. [41], or by a one-step RT-PCR system
(Invitrogen) and high fidelity platinumH Taq as described by Maan
et al [47]. In some cases, full length cDNA copies of AHSV Seg-2
were also synthesised and sequenced, as described by Maan et al
[48]. RT-PCR typing results were also confirmed by sequencing of
amplified cDNA products from Seg-2 and sequence data analysed
using MAFFT [49] and/or Clustal W programs [50]. Phylogenetic
comparisons were made using Neighbour-Joining (NJ) algorithms
and the trees were constructed in Mega 4.1 [51] using nucleotide
RT-PCR Assays for Typing AHSV
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bootstrapped using 500 replicates.
Results
Development of RT-PCR assays and their evaluation for
type specificity
Comparisons of full-length Seg-2 sequences for reference strains
of the nine AHSV serotypes and other field isolates [31,43,52,53,
Bankowska et al – in preparation], were used to identify regions of
conservation within individual AHSV serotypes and variability
between different types. These regions were used to design a
minimum of two serotype-specific primer-pairs for use in RT-PCR
assays to detect each AHSV serotype (Table S1).
The RT-PCR primers were tested in reactions containing RNA
extracted from BHK-21 cells infected with the different AHSV
serotypes (Table 1). The cDNAs generated, were analysed by 1%
agarose gel electrophoresis (AGE), to check both their size and
Table 1. List of AHSV isolates used in this study.
Virus serotype
1 Origin
IAH-P
3 Reference
collection number
Passage history (MB
4/
BHK
5)( V
6/KC1
7/?
8) Other details regarding samples
AHSV Reference Strains
AHSV1 RSA
2 RSArah1/03 MB3/BHK10
AHSV2 RSA RSArah2/03 MB3/BHK7
AHSV3 RSA RSArah3/03 ?/BHK2
AHSV4 RSA RSArah4/03 ?/BHK2
AHSV5 RSA RSArah5/03 MB3/BHK7
AHSV6 RSA RSArah6/03 MB3/BHK6
AHSV7 RSA KENrah7/03 MB4/BHK9
AHSV8 RSA RSArah8/03 ?/BHK2
AHSV9 RSA PAKrah9/03 ?/BHK2
AHSV Field Strains
AHSV2 Ethiopia ETH2010/01 KC1
AHSV2 Senegal SEN2007/01 MB1/BHK2 Sent from ‘The Republique du Senegal, Ministere de
l’elevage’ in May 2007
AHSV2 Senegal SEN2007/02 MB1/BHK3 Same as SEN2007/01 (see above)
AHSV2 Senegal SEN2007/03 MB1/BHK3 From spleen of a six year old male horse, sampled on 26th
August 2007 in Diourbel, Senegal.
AHSV2 Senegal SEN2007/04 MB1/BHK3 From lung of a three year old female horse, sampled on 2nd
September 2007 from Lerane Sambou village, Senegal.
AHSV2 Senegal SEN2007/05 MB1/BHK3 From spleen of a six year old male horse, sampled on 24th
August 2007 from Diongo village, Diourbel, Senegal.
AHSV4 Kenya KEN2007/01 V3 From a horse sampled in Kenya during October 2007 and
passed on Vero cell culture at the Central Veterinary
Research Laboratory (CVRL), Dubai.
AHSV4 Kenya KEN2007/02 V2/KC1 Same as KEN2007/01 (see above)
AHSV4 Spain SPA1987/01 MB1/BHK3
AHSV6 Ethiopia ETH2010/19 KC1
AHSV7 Senegal SEN2007/06 V3 From lung sample of a male horse from Guede Bousso
village Senegal in September 2007
AHSV7 Ethiopia ETH2010/09 V1
AHSV8 Ethiopia ETH2010/10 KC1
AHSV8 Ethiopia ETH2010/11 KC1
AHSV9 & 2 Ethiopia ETH2010/23 KC1
AHSV9 vaccine Senegal SENvvvv/09 ?/BHK2 The Senegal AHSV-9 monovalent vaccine was identified as
‘an original vaccine lot M_0107, BEST BEFORE FEB 2009’
1Bankowska et al – in preparation;
2RSA: Republic of South Africa;
3Institute for Animal Health, Pirbright.
4Number of passages in mouse brain;
5Number of passages in BHK-21 cells;
6Number of passages in Vero cells.
7Number of passages in KC (Culicoides soronensis) cells;
8Unknown.
IAH-P ‘dsRNA virus reference collection number’ composed of ‘country code, year, and the number of the isolate in that year from that country. Full details of these
isolates are available on the dsRNA virus reference collection website [44].
doi:10.1371/journal.pone.0025686.t001
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were generated from RNA of the homologous serotype (Figure 1
panels A–D). None of the primer-pairs amplified cDNAs from RNA
of even the most closely related heterologous AHSV types, or from
members of other related Orbivirus species (data not shown). These
initial evaluations confirm in silico analyses, indicating that the
primers listed in Table S1 are indeed ‘type-specific’.
IdentificationofAHSV-2 isolates fromSenegal 2007. RNA
was extracted from equine samples, or from cell culture supernatants
infected with these viruses (SEN2007/01, SEN2007/02, SEN2007/
03, SEN2007/04 and SEN2007/05). In each casea strong +veband
of the expected size (1179 Kb) was generated inSeg-7 group-specific
RT-PCR assays (Figure 2 – panel A). The RNA samples were also
tested by conventional RT-PCR, using Seg-2 specific primers listed
in Table S1. Strong +ve bands of the expected sizes were only
generated with primer-pairs ‘2A1’ and ‘2A2’, demonstrating the
presence of AHSV-2 RNA. None of the other AHSV types were
detected, including AHSV-9 (which had recently been used to
vaccinate the animals) (Figure 3). The AHSV-2 Seg-2 amplicons
were sequenced, generating data for nucleotides (nt) 500–1648,
which showed 97% nt identity with Seg-2 of the South African
reference strain of AHSV-2 (Ac. No. AY163332) (Figure 4).
Identification of AHSV-7 from Senegal 2007. AHSV
isolate (SEN2007/06) derived from a horse that died in 2007,
was also tested in type-specific RT-PCR assays for each of the nine
AHSV serotypes. Assays containing only one of the type 7 specific
primers (‘7A1’) (Table S1) generated a band of the expected size
(1426 bp) indicating that this sample contains AHSV-7 (Figure 3 –
panel C). Although the other type 7 specific primers (‘7A2’)
worked well with the reference strain RSArah7/03 and Ethiopian
strain (ETH2010/09), they failed to amplify sequences from
SEN2007/06, suggesting a significant variation in the footprint
sequence for this primer-pair compared to the reference strain
(Table S1). The ‘7A1’ Seg-2 amplicon (nt 550–1800) from
SEN2007/06, was also sequenced, showing 92% nt identity
overall to Seg-2 of the South African AHSV-7 reference strain (Ac.
No. AY163330) confirming the isolate as AHSV-7 (Figure 4).
AHSV-9 vaccine strain from Senegal 2007. The virus
species of the original Senegal vaccine strain (SENvvvv/09) was
confirmed (as AHSV) by the synthesis of an 1179 Kb cDNA in
Figure 1. ‘Type-specific’ primers for Seg-2 of AHSV-1 to AHSV-9. The cDNAs amplified from Seg-2 of AHSV 1–9 serotypes using type-specific
primers were analyzed by 1% agarose-gel-electrophoresis (AGE). Panel A: Lanes 1 and 2 show products from AHSV-1/RSArah1/03 using primer-pairs
‘1A1’ (1793 bp) and ‘1A2’ (1452 bp) respectively. Lanes 3 and 4: Primer-pairs ‘1A1’ and ‘1A2’ amplified only small amounts of ‘incorrectly’ sized
products from AHSV-2/RSArah2/03 (heterologous-control). Lanes 5 and 6 show products from AHSV-2/RSArah2/03 using primer-pairs ‘2A1’ (1098 bp)
and ‘2A2’ (1339 bp) respectively. Lanes 7 and 8: Primer-pairs ‘2A1’ amplified none but ‘2A2’ amplified only small amounts of ‘incorrectly’ sized
products from AHSV-1/RSArah1/03 (heterologous-control). Lanes 9 and 10 show products from AHSV-3/RSArah3/03 using primer-pairs ‘3A1’ (751 bp)
and ‘3A2’ (1524 bp) respectively. Lanes 11 and 12: Primer-pairs ‘3A1’ and ‘3A2’ showed no amplification from AHSV-7/KENrah7/03 (heterologous-
control). Panel B: Lanes 1 and 2 show products from AHSV-4/RSArah4/03 using primer-pairs ‘4A1’ (1264 bp) and ‘4A3’ (1471 bp) respectively. Lanes
3, 4, 5 and 6: Primer-pairs ‘4A1’ and ‘4A3’ did not amplify Seg-2 from AHSV-5/RSArah5/03 and AHSV-8/RSArah8/03 respectively (heterologous-control).
Lanes 7 and 8 show products from AHSV-5/RSArah8/03 using primer-pairs ‘5A2’ (1423 bp) and ‘5A3’ (1139 bp) respectively. Lanes 9, 10, 11 and 12:
Primer-pairs ‘5A2’ and ‘5A3’ did not amplify Seg-2 from AHSV-4/RSArah4/03 and AHSV-8/RSArah8/03 respectively (heterologous-control). Panel C:
Lanes 1 and 2 show products from AHSV-6/RSArah6/03 using primer-pairs ‘6A1’ (1154 bp) and ‘6A2’ (1270 bp) respectively. Lanes 3 and 4: Primer-
pairs ‘6A1’ and ‘6A2’ amplified only small amounts of ‘incorrectly’ sized products from AHSV-8/RSArah8/03 (heterologous-control). Lanes 5 and 6
show products from AHSV-7/KENrah7/03 using primer-pairs ‘7A1’ (1426 bp) and ‘7A2’ (1426 bp) respectively. Lanes 7 and 8: Primer-pairs ‘7A1’ and
‘2A2’ amplified only small amounts of ‘incorrectly’ sized products from AHSV-3/RSArah3/03 (heterologous-control). Panel D: Lanes 1 and 2 show
products from AHSV-8/RSArah3/03 using primer-pairs ‘8A1’ (1757 bp) and ‘8A2’ (1732 bp) respectively. Lanes 3, 4, 5 and 6: Primer-pairs ‘8A1’ and
‘8A2’ did not amplify Seg-2 from AHSV-4/RSArah4/03 and AHSV-5/RSArah5/03 respectively (heterologous-control). Lanes 7 and 8 show products from
AHSV-9/PAKrah9/03 using primer-pairs ‘9A1’ (1483 bp) and ‘9A2’ (1706 bp) respectively. Lanes 9 and 10: Primer-pairs ‘9A1’ and ‘9A2’ did not amplify
Seg-2 from AHSV-6/RSArah6/03 (heterologous-control). Lane M: 1 Kb DNA marker (Invitrogen).
doi:10.1371/journal.pone.0025686.g001
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In subsequent type-specific assays, only two primer sets targeting
Seg-2 of AHSV-9 (‘9A1’ and ‘9A2’) (Table S1) generated strong
cDNA bands of the expected size, indicating that the vaccine did
not contain other AHSV types (Figure 3 – panel D). The Seg-2
amplicons were sequenced (nt 520–1684) showing 98.8% nt
identity with Seg-2 of the South African AHSV-9 reference strain
(Ac. No. AF043926) confirming the virus type (Figure 4).
AHSV-4 isolates from Kenya 2007. RNA extracted from
Kenyan isolates KEN2007/01 and KEN2007/02 were tested in
conventionaltype-specificRT-PCRassaystargetingSeg-2(Figures4
and 5). Only primer-pairs ‘4A1’, ‘4A2’ and ‘4A3’ generated strong
Figure 2. Electrophoretic analysis of cDNA products generated in AHSV group-specific RT-PCR assays using Seg-7 specific primers.
PCR amplicons of 1179 bp were generated from AHSV Seg-7 specific RT-PCR of dsRNA extracted from equine lung and spleen extracts and vaccine
strain from Senegal tested in duplicate (SEN2007/01 – lanes 1 and 2; SEN2007/02 – lanes 3 and 4 in panel A; SENvvvv/09 – lanes 1 and 2 in panel B
respectively) [46], demonstrating that the samples contain AHSV RNA. Lane 2C is a negative water control showing no amplification. Lane M: 1 Kb
marker (Invitrogen). RNA from BTV-4/RSArrrr/04 was used as a positive control using primer-pair ‘4W2’ - 2324 bp [41] (lane +C, panel B).
doi:10.1371/journal.pone.0025686.g002
Figure 3. Electrophoretic analysis of cDNA from Seg-2 of AHSV isolates from Senegal 2007 using ‘type-specific’ primer-pairs. Panel
A and B: PCR amplicons were generated from AHSV Seg-2 specific RT-PCR of dsRNA extracted from equine lung (SEN2007/01 – panel A) and spleen
(SEN2007/02 – panel B) using primer-pairs ‘2A1’ (1098 bp, lane 5 in both panels) and ‘2A2’ (1339 bp, lane 6 in both panels) (Table S1), demonstrating
that the samples contain AHSV-2 RNA. Lanes 3–20 represent RNA tested from AHSV-1 to 9 using two pairs of primers for each serotypes. Lane 1 is a
negative water control showing no amplification. Lane M: 1 Kb marker (Invitrogen). RNA from BTV-4/RSArrrr/04 was used as a positive control using
primer-pair ‘4W2’ - 2324 bp [41] (lane 2). Panel C: PCR amplicons were generated from AHSV Seg-2 specific RT-PCR of dsRNA extracted from
SEN2007/06 using primer-pairs ‘7A1’ (1426 bp - lane 7) (Table S1), demonstrating that the samples contain AHSV-7 RNA. Lanes 1–9 represent RNA
tested from AHSV-1 to 9 using first set of primers for each serotypes. No amplification was detected in other serotypes. Lane 2C is a negative water
control showing no amplification. Lane M: 1 Kb marker (Invitrogen). RNA from ASHV multivalent vaccine strain (SENvvv1/MV) with ‘3A1’ was used as
positive control which generated a product of 751 bp (lane +C). Panel D: PCR amplicons were generated from AHSV Seg-2 specific RT-PCR of dsRNA
extracted from SENvvvv/09 using primer-pairs ‘9A1’ (1483 bp - lane 18) and ‘9A2’ (1706 bp – lane 19) (Table S1), demonstrating that this sample
contains AHSV-9 RNA. Lanes 3–20 represent RNA tested from AHSV-1 to 9 using two pairs of primers for each serotypes. Lane 1 is a negative water
control showing no amplification. Lane M: 1 Kb marker (Invitrogen). RNA from BTV-4/RSArrrr/04 was used as a positive control using primer-pair ‘4W2’
- 2324 bp [41] (lane 2).
doi:10.1371/journal.pone.0025686.g003
RT-PCR Assays for Typing AHSV
PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e25686bands of the expected sizes (1264 bp, 1463 bp and 1471 bp
respectively) identifying the virus as AHSV-4. This indicates that
these isolates did not contain RNA from other recognised AHSV
serotypes. The Seg-2 amplicons were sequenced, showing 96% nt
identity with Seg-2 of the South African AHSV-4 reference strain
(Ac. No. M90697) confirming the virus type (Figure 4).
Discussion
AHSV Seg-2 encodes VP2 (the main serotype-specific antigen
and most variable of the virus proteins) and shows 47.6% to 71.4%
nt identity between types, which can therefore be identified by
phylogenetic comparisons [31,43, Bankowska et al – in prepara-
tion]. Cross-hybridization methods [54] or hybridization and real-
time RT-PCR methods targeting AHSV Seg-2 have previously
been described [55,56]. Sailleau, et al [42] have also reported
typing of AHSV using a serogroup-specific forward-primer and a
serotype-specific reverse-primer, based on a limited Seg-2 dataset.
These primer-pairs generated a small amplicon for each of nine
serotypes of AHSV and were used to ‘type’ a limited number of
reference and field strains. The RT-PCR assay results obtained
were also compared with VNT results but were not confirmed by
sequencing of the resulting amplicons.
Recent full length sequencing of Seg-2 from reference strains
and multiple field strains of AHSV (Bankowska et al – in
preparation), have supported the design of additional AHSV ‘type-
specific’ primer-pairs. We have successfully evaluated these
primers, RT-PCR assays, sequencing and phylogenetic analyses,
for differentiation of individual AHSV strains even within a single
serotype. These techniques can determine AHSV serotype with
greater accuracy, sensitivity and significantly more quickly than is
possible by current serological techniques, facilitating surveillance
and molecular epidemiology studies of the virus.
The relatively small number of AHSV isolates (N=26 (Table 1);
N=107 in silico (Table S1)) that are available for sequence analyses
and testing, has limited wider validation of the assays developed
reported here. The specificity of the primers therefore primarily
reflects their failure to recognise and amplify Seg-2 of other AHSV
serotypes, rather than an ability to detect all possible isolates of the
homologous type. If in future studies, any of these primers fail to
detect Seg-2 of a novel isolate, it will be sequenced, providing a
basis for further ‘evolution’ of primer sequences and assays. The
‘fine-scale’ differentiation and identification of individual AHSV
strains, depends on the availability and characterisation of well
documented reference isolates from different locations and
belonging to different virus lineages. These need to be stored
and maintained in a suitable reference collection (like the ORC)
with links to relevant sequence data [44].
Recent disease outbreaks caused by AHSV-4 in Kenya (in
2007); AHSV-2, AHSV-7 and AHSV-9 in Senegal (in 2007), were
identified using the ‘type-specific’ assays (as described here).
Serotype 9 was also identified in the Gambia (in 2009) along with
multiple serotypes in Ethiopia (in 2010) using the same techniques
[15], Bankowska et al, in preparation]. These novel laboratory
Figure 4. Neighbour-Joining tree, showing relationships in Seg-2 between reference and field strains of AHSV. The tree was
constructed using distance matrices, generated using the p-distance determination algorithm in MEGA 4.1 (500 bootstrap replicates) [51]. AHSV split
into distinct groups based on Seg-2 sequences, reflecting serological relationships between virus strains [31]. Reference strains of AHSV are showni n
black and field isolates are shown in blue font. Isolate designations: IAH ‘dsRNA virus reference collection number composed of ‘country code, year,
and the number of the isolate in that year from that country [44]. Seg-2 sequences of two Senegalese AHSV-2 field 2007 strains showed 99.8%
nucleotide (nt) identity to each other and showed 97% nt identity to the AHSV-2 reference strain (500–1648 nt). AHSV-4/KEN2007/01 showed 96%
nucleotide identity to the AHSV-4 published Seq-2 sequence in the upstream 1170 base pairs (480–1650 nt). Seg-2 (550–1800 nt) of Senegalese
AHSV-7 strain from 2007 showed 92% identity to the AHSV-7 South African reference strain. Seg-2 (520–1684 nt) of Senegalese vaccine strain of type
9 showed 98.8% identity to the AHSV-9 South African reference strain. Scale represents number of substitutions per site. Values at major branching
points represent NJ bootstraps.
doi:10.1371/journal.pone.0025686.g004
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require reference antisera or virus isolates that may have limited
availability and which themselves represent a potential disease
security risk. These methods are robust and versatile, reliably
identifying AHSV type within 24 h of sample receipt, with no
evidence of cross-amplification of other related types or other
orbiviruses. Although slower than real-time RT-PCR assays, these
conventional type-specific primers and assays can be used to
generate cDNA amplicons for sequence analyses, providing
definitive proof of relationships between Seg-2 of individual virus
strains.
These phylogenetic comparisons will help to determine the
prevalence, distribution and movements of different AHSV
serotypes and topotypes, improving our understanding of the
epidemiology and transmission of the virus, providing a basis for
the design and rapid implementation of control strategies,
including vaccination.
Supporting Information
Table S1 Primers for specific amplification of Seg-2
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